QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud

Author
SySAdmin
Posted
October 17, 2014
Views
1675

Page All:

Page 1
QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud

SAN DIEGO and HILDEN, Germany, October 17, 2014 /PRNewswire/ --

       
        - Translational research in cancer and other diseases will benefit from new
          capabilities being presented at the American Society of Human Genetics annual meeting
        - Volume of 250,000-plus DNA samples linked to Ingenuity(R) Knowledge Base
          greatly exceeds any comparable database - providing superior depth for genomic
          analysis
        - Ingenuity(R) Variant Analysis(TM) adds fully integrated BIOBASE HGMD(R)
          Professional to deliver quick, detailed reports on inherited mutations
        - CLC Cancer Research Workbench gains copy number detection and first
          "FastQ-to-insight" solution through integration with Ingenuity(R) Variant Analysis(TM)
          to help users uncover meaningful insights in cancer research

    QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a number of
new capabilities for its Ingenuity(R) Variant Analysis(TM) and CLC Cancer Research
Workbench solutions that accelerate the workflows for researchers to move from sample to
insight with next-generation sequencing (NGS). The company is demonstrating the latest
workflows for analysis and interpretation of NGS data, focused on hereditary disease and
detection of somatic driver mutations in cancer, at the American Society of Human Genetics
(ASHG) annual meeting from October 18-22 in San Diego, California.

    "Adoption of QIAGEN's universal bioinformatics solutions is growing rapidly as we
continue to integrate and expand the capabilities of our applications and knowledge bases
from CLC bio, Ingenuity and BIOBASE. Thousands of researchers to date have already
analyzed over 250,000 human DNA samples using QIAGEN bioinformatics products," said Dr.
Laura Furmanski, Senior Vice President of QIAGEN and head of the Bioinformatics Business
Area. "Data analysis and interpretation remain a significant bottleneck in next-generation
sequencing. We are increasing QIAGEN's leadership in bioinformatics by further integrating
and expanding our portfolio of universal solutions to enable disease-focused researchers
to move rapidly from raw data to valuable insights. We are pleased to demonstrate our
streamlined, advanced analysis workflows for translational research, other scientific
fields and clinical applications to the human genetics community at ASHG."

    Ingenuity Variant Analysis integrates BIOBASE HGMD

    QIAGEN's Ingenuity Variant Analysis is a web-based software application that quickly
filters genetic variants in a secure, private cloud-based environment to identify variants
most likely to cause disease. Ingenuity applications provide researchers a powerful
platform to efficiently evaluate data generated by high-throughput NGS technologies.
Ingenuity Variant Analysis leverages the Ingenuity Knowledge Base, a repository of
expertly curated biological interactions and functional annotations created from millions
of individually modeled relationships between proteins, genes, complexes, cells, tissues,
drugs, and diseases. To support users focused on hereditary disease, QIAGEN now has fully
integrated HGMD Professional with Ingenuity Variant Analysis so that researchers no longer
require a separate HGMD license. HGMD is a unique resource that provides comprehensive
data on human inherited disease mutations and is widely used in human genetics research,
diagnostics and personal genomics applications. Through this integration, users can now
utilize ethnicity inference to simplify dataset groupings and to identify variants
associated with target traits (such as high cholesterol or physical traits) at no
additional cost.

    CLC Cancer Research Workbench adds CNV detection and integration with Ingenuity
Variant Analysis

    QIAGEN's CLC Cancer Research Workbench, the first comprehensive, user-friendly and
customizable cancer-focused informatics solution, provides scientists and clinicians with
tools to discover prognostic markers, identify subclonal somatic mutations, detect
inherited traits, find biomarkers for drug response, and determine new oncogenes. All
results can be filtered, visualized and compared with relevant databases. Users will now
also be able to detect copy number variations (CNVs) and variants from RNA-seq data, which
can be further analyzed using Ingenuity Variant Analysis for causal variant
identification. QIAGEN has also developed the first "FastQ-to-insight solution," which
integrates CLC Cancer Research Workbench directly with Ingenuity Variant Analysis. This
new Workbench plug-in allows users to identify and interpret somatic cancer driver
mutations with one click using Ingenuity Variant Analysis and to visualize the results in
both products to identify and validate the best candidates. A demonstration of this new
tool will be shown at ASHG. The product's launch is expected at the end of October.

    QIAGEN Presence at ASHG

    QIAGEN scientists will be discussing Ingenuity and CLC bio solutions in the company's
booth (#936-938) throughout the meeting and also during an Exhibitor Education Event in
Room 11A at the Convention Center on Tuesday Oct. 21 from 12:30-1:45 p.m. In addition,
more than 30 posters will highlight the use of Ingenuity and CLC bio products, including:

    Saturday, Oct. 18, HGVS meeting (preconference of ASHG)

       
        - Comparison and interpretation of variants in RNA and DNA from sarcoma
          cancer sample

    Sunday, Oct. 19, 5-6 p.m.

       
        - Comparing variant filters from transcriptome and exome sequencing data
          (#1578S)
        - Exome sequencing of multiplex oral clefts families detects recurrent shared
          rare variants in nine genes (#742S)

    Tuesday, Oct. 21, 2-3 p.m.

       
        - Identification of differentially-expressed genes and somatic mutations in
          esophageal adenocarcinoma cancer patients (# 1391T)

    About QIAGEN

    QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of
Sample & Assay Technologies that are used to transform biological materials into valuable
molecular information. Sample technologies are used to isolate and process DNA, RNA and
proteins from biological samples such as blood or tissue. Assay technologies are then used
to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets
more than 500 products around the world, selling both consumable kits and automation
systems to customers through four customer classes: Molecular Diagnostics (human
healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma
(pharmaceutical and biotechnology companies) and Academia (life sciences research). As of
June 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.

    Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended.
To the extent that any of the statements contained herein relating to QIAGEN's products,
markets, strategy or operating results, including without limitation its expected
operating results, are forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks. Such uncertainties and
risks include, but are not limited to, risks associated with management of growth and
international operations (including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating results and allocations
between customer classes, the commercial development of markets for our products in
applied testing
[http://www.qiagen.com/About-Us/Press-Releases/PressReleaseView/?PressReleaseID@5&lang=EN ]
, personalized healthcare, clinical research, proteomics
[http://www.qiagen.com/About-Us/Press-Releases/PressReleaseView/?PressReleaseID@5&lang=EN ]
, women's health/HPV
[http://www.qiagen.com/About-Us/Press-Releases/PressReleaseView/?PressReleaseID@5&lang=EN ]
testing and nucleic acid
[http://www.qiagen.com/About-Us/Press-Releases/PressReleaseView/?PressReleaseID@5&lang=EN ]
-based molecular diagnostics
[http://www.qiagen.com/About-Us/Press-Releases/PressReleaseView/?PressReleaseID@5&lang=EN ]
; changing relationships with customers, suppliers and strategic partners; competition;
rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the level and timing of
customers' funding, budgets and other factors); our ability to obtain regulatory approval
of our products; difficulties in successfully adapting QIAGEN's products to integrated
solutions and producing such products; the ability of QIAGEN to identify and develop new
products and to differentiate and protect our products from competitors' products; market
acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration
of acquired technologies and businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities
and Exchange Commission (SEC).

       
        Contacts:

        QIAGEN
        Investor Relations
        John Gilardi
        +49-2103-29-11711
        e-mail: ir@QIAGEN.com

        Public Relations
        Dr. Thomas Theuringer
        +49-2103-29-11826
        e-mail: pr@QIAGEN.com

Qiagen

Title

Medium Image View Large